You searched for prescription-drugs | Page 16 of 171

Medicare Advantage 2025 Spotlight: A First Look at Plan Premiums and Benefits

Nov 15, 2024

Issue Brief

This brief provides an overview of premiums and benefits in Medicare Advantage plans that are available for 2025 and key trends over time. Two-thirds of all Medicare Advantage plans with Part D prescription drug coverage (MA-PDs) (67%) will charge no premium (other than the Part B premium) in 2025, similar to 2024 (66%). Nearly all Medicare Advantage plans (97% or more) are offering vision, dental and hearing, as they have in previous years. However, the share of plans offering certain benefits has declined, such as over-the-counter benefits (85% in 2024 vs. 72% in 2025), remote access technologies (74% in 2024 vs. 53% in 2025), meal benefits (72% in 2024 vs. 65% in 2025) and transportation (36% in 2024 vs. 29% in 2025).

Oral Contraceptive Pills: Access and Availability

Mar 20, 2024

Issue Brief

This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.

10 Reasons Why Medicare Advantage Enrollment is Growing and Why It Matters

Jan 30, 2024

Issue Brief

This issue briefs lays out 10 reasons why Medicare Advantage enrollment has been growing and why we can expect more growth in the years to come.

Which Federal Agencies Make Medicare Work and How Were They Affected by Recent Changes Made by the Trump Administration?

Jun 4, 2025

Issue Brief

This brief highlights some of the key federal agencies and offices that play a role in making Medicare work and, to the extent possible, describes the recent staffing and organizational changes made by the Trump administration that could affect the operations of Medicare in the future.

Health Cost and Affordability Policy Issues and Trends to Watch in 2024

Jan 24, 2024

Issue Brief

While issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public.

Medicare Advantage Plans Denied a Larger Share of Prior Authorization Requests in 2022 Than in Prior Years

Aug 8, 2024

News Release

Medicare Advantage plans denied 3.4 million prior authorization requests for health care services in whole or in part in 2022, or 7.4% of the 46.2 million requests submitted on behalf of enrollees that year, according to a new KFF analysis of federal data. That was a higher share of denials than in recent years.

Poll: By a Wide Margin, Democratic Voters Now Care More About the Affordable Care Act Than Republican Voters Do, And Voters Trust Democrats More Than Republicans to Handle Its Future

Dec 1, 2023

News Release

The future of the Affordable Care Act, an issue that was once a key health care issue for Republican voters, is now more important to Democratic voters, a new KFF Health Tracking Poll finds.

Supreme Court Decision Limiting the Authority of Federal Agencies Could Have Far-Reaching Impacts for Health Policy

Jul 1, 2024

Issue Brief

On June 28, 2024, the U.S. Supreme Court overturned a longstanding legal precedent that required federal courts to defer to reasonable agency interpretation when statutes are ambiguous. The decision will shift many policy decisions from federal agencies to federal judges, with implications for health policy that will reverberate for years to come. This issue brief examines the decision and assesses what’s ahead.

Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease

May 10, 2024

News Release

About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds.

An Estimated 1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to Reduce Heart Risk

Apr 24, 2024

News Release

In a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients.

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

Search

Filter